


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 8 Jul 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
HSMN NewsFeed - 30 Jun 2025
NewLines(TM) App Update Extends AI-Assisted SmartProfiles(TM) to the Android Platform
NewLines(TM) App Update Extends AI-Assisted SmartProfiles(TM) to the Android Platform
HSMN NewsFeed - 25 Jun 2025
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
HSMN NewsFeed - 16 Jun 2025
Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
HSMN NewsFeed - 23 May 2025
England's NICE Recommends FILSPARI(R) (sparsentan) as a Treatment Option for IgA Nephropathy
England's NICE Recommends FILSPARI(R) (sparsentan) as a Treatment Option for IgA Nephropathy
